Edesa Biotech, Inc. quarterly report, Q3 FY2023

Full document

Edesa Biotech, Inc. — Form 10-Q Summary

Reporting period: Fiscal third quarter and first nine months ended June 30, 2023; filed August 9, 2023. The company is a clinical-stage biopharmaceutical developer and reported no product revenue.

Financial performance and position

  • Quarter: Operating expenses were $2.06 million, down from $5.80 million in the prior-year quarter. Net loss was $1.98 million ($0.10 per share), versus $5.79 million ($0.37 per share).
  • Nine months: Operating expenses were $6.85 million, down from $15.53 million. Net loss was $6.65 million ($0.34 per share), versus $14.74 million ($1.04 per share).
  • Expense drivers: Lower R&D spending reflected reduced clinical-study and drug-manufacturing costs; the prior-year quarter included $2.54 million for EB05 bulk drug product. Lower G&A reflected reduced personnel costs and share-based compensation. The prior-year nine-month period also included $0.78 million of grant income; the Canadian grant program is complete and reimbursements have been received.
  • Cash flow: Operating cash use was $5.17 million for the nine months, compared with $6.65 million. Financing provided $4.42 million, principally from equity sales and warrant exercises. Cash declined by $0.63 million to $6.46 million.
  • Liquidity: Current assets were $6.91 million and current liabilities $1.53 million; working capital was $5.39 million. Total assets were $9.42 million and shareholders’ equity $7.85 million. No conventional borrowings were reported; liabilities included $114,921 in lease obligations.
  • Margins: Not meaningful because the company reported no revenue. The filing does not provide a revenue or commercial-profit outlook.

Material changes and financing

  • Cash decreased from $7.09 million at September 30, 2022, while total shareholders’ equity fell from $9.39 million to $7.85 million. Common shares outstanding rose from 16.66 million to 20.87 million by June 30, primarily reflecting equity issuance and warrant exercises.
  • A November 2022 private placement generated approximately $2.91 million in net proceeds. During the nine months, warrant exercises provided $0.77 million. The March 2023 ATM program allows up to $20 million in gross sales, subject to offering limitations then permitting up to $8.37 million; $0.69 million net was raised in the quarter. After quarter-end, the ATM issued 226,882 shares for $0.19 million net.
  • Management said it plans to fund operations over the next 12 months with cash on hand and ATM sales, while retaining flexibility to adjust spending. It expects to seek additional financing, but availability and terms are uncertain. Further equity issuance may dilute shareholders.

Pipeline, outlook, and risks

  • EB05 (paridiprubart): The company is enrolling in the Phase 3 portion of its ARDS study in hospitalized COVID-19 patients. The agreed U.S. design targets about 600 evaluable patients on invasive mechanical ventilation, with 28-day mortality as the primary endpoint. Enrollment expansion from 23 to as many as 60 U.S. and Canadian hospitals is conditional on funding. The company is also evaluating approaches to study non-COVID ARDS; any protocol changes could affect how previously enrolled subjects are analyzed.
  • EB01 (daniluromer): Preliminary Phase 2b results showed statistically significant improvement versus placebo for the primary and a key secondary endpoint at the 1.0% concentration. The company said it was preparing for an FDA End-of-Phase-2 meeting following full analysis; preliminary findings are not definitive trial results.
  • Other candidates: Health Canada approved a clinical trial application for a future EB06 Phase 2 vitiligo study. The company was preparing a U.S. IND for a future EB07 Phase 2 systemic-sclerosis study.
  • Key risks and commitments: Continued operating losses, uncertain access to financing, trial recruitment and development risks, and foreign-exchange exposure (management estimated a 10% exchange-rate change could affect loss and comprehensive loss by about $0.3 million). Contracted research and other commitments totaled approximately $1.93 million. Separate license agreements include contingent future milestones of up to $356 million, $18.4 million, and $68.9 million, plus potential royalties or sublicensing payments; these amounts depend on future milestones or commercial activity.
  • Management reported no material change to previously disclosed risk factors, no material legal proceedings outside the ordinary course, and effective disclosure controls as of June 30, 2023.

Investor facts to verify

  • Current cash burn, remaining ATM capacity and the actual duration of available funding, including the effect of planned clinical-trial spending.
  • Enrollment pace, site expansion, protocol status, and the timing and evidentiary strength of EB05 Phase 3 results.
  • Full analysis and regulatory feedback on EB01’s Phase 2b results and the status of planned EB06 and EB07 studies.
  • Potential dilution from outstanding warrants, options, restricted share units, and future financing; the filing reported 5.61 million warrants outstanding at June 30.
  • Material terms and potential costs of the August 4, 2023 amended executive employment agreements, including severance and change-of-control provisions.